



RECEIVED

2005 DEC -2 P 3:22

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

24 November, 2005



Securities and Exchange Commission  
Division of Corporate Finance  
Office of International Corporate Finance  
450 Fifth Street, N.W.  
Washington D.C. 20549  
U.S.A.

EXPRESS POST

Dear Sir/Madam,

Re: **Metabolic Pharmaceuticals Limited (FILE NO. 82-34880)**  
**submission of information filed with Australian Stock Exchange (ASX)**  
**and Australian Securities and Investment Commission (ASIC)**  
**pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934**

SUPPL

Please find attached copies of announcements lodged with the ASX and ASIC:

Date of Announcement/Lodgement	To:	Title	No of Pages
18 November 2005	ASX	Change of Director's Interest Notice	3
24 November 2005	ASX	Change of Director's Interest Notice	3

Yours faithfully,  
Metabolic Pharmaceuticals Limited

Belinda Shave  
Financial Controller & Company Secretary

PROCESSED


DEC 05 2005

J THOMSON  
FINANCIAL

RECEIVED

2005 DEC -2 P 3:12

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE



ASX

AUSTRALIAN STOCK EXCHANGE

Australian Stock Exchange Limited  
ABN 98 008 624 691  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

PO Box H224  
Australia Square  
NSW 1215

Telephone 61 2 9227 0334

Internet <http://www.asx.com.au>  
DX 10427 Stock Exchange Sydney

**FACSIMILE**

**Department: COMPANY ANNOUNCEMENTS OFFICE**

DATE: 18/11/2005

TIME: 12:55:31

TO: METABOLIC PHARMACEUTICALS LIMITED

FAX NO: 03-9860-5777

FROM: AUSTRALIAN STOCK EXCHANGE LIMITED - Company Announcements Office

SUBJECT: CONFIRMATION OF RECEIPT AND RELEASE OF ANNOUNCEMENT

**MESSAGE:**

We confirm the receipt and release to the market of an announcement regarding:

Change of Director's Interest Notice

**If ASX considers an announcement to be sensitive, trading will be halted for 10 minutes.**

If your announcement is classified by ASX as sensitive, your company's securities will be placed into "pre-open" status on ASX's trading system. This means that trading in your company's securities is temporarily stopped, to allow the market time to assess the contents of your announcement. "Pre-open" is approx. 10 minutes for most announcements but can be 50 minutes (approx) for takeover announcements.

Once "pre-open" period is completed, full trading of the company's securities recommences.

**PLEASE NOTE:**

In accordance with Guidance Note 14 of ASX Listing Rules, it is mandatory to elodge announcements using ASX Online. Fax is available for emergency purposes and costs A\$38.50 (incl. GST). The only fax number to use is 1900 999 279.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

<b>Name of entity</b>	<b>METABOLIC PHARMACEUTICALS LIMITED</b>
<b>ABN</b>	<b>96 083 866 862</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>ARTHUR EMMETT</b>
<b>Date of last notice</b>	<b>4 AUGUST, 2005</b>

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(a) <b>Directly held</b> (b) <b>Indirectly held</b>
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	(a) <b>ARTHUR EMMETT</b> (b) <b>THE WEST WIALONG A/C</b>
<b>Date of change</b>	<b>18 NOVEMBER 2005</b>
<b>No. of securities held prior to change</b>	a) <b>DIRECTLY HELD</b> by Arthur Emmett: - 257,692 Fully Paid Ordinary Shares (ASX Code: MBP)  (b) <b>INDIRECTLY HELD</b> by The West Wialong A/C: - 136,500 Fully Paid Ordinary Shares (ASX Code: MBP)
<b>Class</b>	<b>Ordinary Fully Paid Shares (ASX Code: MBP)</b>
<b>Number acquired</b>	<b>100,000 Ordinary fully Paid Shares (ASX Code: MBP)</b>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number disposed</b>	<b>Nil</b>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<b>\$48,500</b>
<b>No. of securities held after change</b>	<b>a) DIRECTLY HELD by Arthur Emmett:</b> <ul style="list-style-type: none"> <li>- 357,692 Fully Paid Ordinary Shares (ASX Code: MBP)</li> </ul> <b>(b) INDIRECTLY HELD by The West Wialong A/C:</b> <ul style="list-style-type: none"> <li>- 136,500 Fully Paid Ordinary Shares (ASX Code: MBP)</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<b>On market purchase</b>

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	<b>NIL</b>
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

## Belinda Shave

---

**From:** ASX.Online@asx.com.au  
**Sent:** Friday, 18 November 2005 12:56 PM  
**To:** Belinda Shave; Chris Belyea; Diana Attana; Peter Dawson; Roland Scollay  
**Subject:** MBP - ASX Online e-Lodgement - Confirmation of Release

**Attachments:** 283858.pdf



283858.pdf (103  
KB)

ASX confirms the release to the market of Doc ID: 283858 as follows:  
Release Time: 18-Nov-2005 12:55:22  
ASX Code: MBP  
File Name: 283858.pdf  
Your Announcement Title: Change of Directors Interest Notice - Chairman



**ASX**

AUSTRALIAN STOCK EXCHANGE

Australian Stock Exchange Limited  
ABN 98 008 624 691  
Exchange Centre  
Level 4, 20 Bridge Street  
Sydney NSW 2000

PO Box H224  
Australia Square  
NSW 1215

Telephone 61 2 9227 0334

Internet <http://www.asx.com.au>  
DX 10427 Stock Exchange Sydney

**FACSIMILE**

**Department: COMPANY ANNOUNCEMENTS OFFICE**

**DATE:** 24/11/2005

**TIME:** 13:25:04

**TO:** METABOLIC PHARMACEUTICALS LIMITED

**FAX NO:** 03-9860-5777

**FROM:** AUSTRALIAN STOCK EXCHANGE LIMITED - Company Announcements Office

**SUBJECT:** CONFIRMATION OF RECEIPT AND RELEASE OF ANNOUNCEMENT

**MESSAGE:**

We confirm the receipt and release to the market of an announcement regarding:

Change of Director's Interest Notice

**If ASX considers an announcement to be sensitive, trading will be halted for 10 minutes.**

If your announcement is classified by ASX as sensitive, your company's securities will be placed into "pre-open" status on ASX's trading system. This means that trading in your company's securities is temporarily stopped, to allow the market time to assess the contents of your announcement. "Pre-open" is approx. 10 minutes for most announcements but can be 50 minutes (approx) for takeover announcements.

Once "pre-open" period is completed, full trading of the company's securities recommences.

**PLEASE NOTE:**

In accordance with Guidance Note 14 of ASX Listing Rules, it is mandatory to lodge announcements using ASX Online. Fax is available for emergency purposes and costs A\$38.50 (incl. GST). The only fax number to use is 1900 999 279.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>METABOLIC PHARMACEUTICALS LIMITED</b>
<b>ABN</b>	<b>96 083 866 862</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>PATRICK SUTCH</b>
<b>Date of last notice</b>	<b>17 May 2004</b>

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<b>DIRECTLY HELD</b>
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	NIL
<b>Date of change</b>	24 NOVEMBER 2005
<b>No. of securities held prior to change</b>	NIL
<b>Class</b>	Fully Paid Ordinary Shares
<b>Number acquired</b>	15,000
<b>Number disposed</b>	NIL
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$6,600
<b>No. of securities held after change</b>	15,000 Fully Paid Ordinary Shares (ASX Code: MBP)
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On market purchase.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	NIL
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

---

+ See chapter 19 for defined terms.